Cyclerion Therapeutics (CYCN) Change in Accured Expenses (2018 - 2025)
Cyclerion Therapeutics (CYCN) posted quarterly Change in Accured Expenses of $85000.0 for Q3 2025, up 140.48% year-over-year from $35346.5 in Q3 2024, and up 161.59% quarter-over-quarter from -$138000.0 in Q2 2025.
Cyclerion Therapeutics (CYCN) Change in Accured Expenses (2018 - 2025) Analysis & Trends
Cyclerion Therapeutics' Change in Accured Expenses history runs 8 years deep, the most recent figure standing at $85000.0 for Q3 2025.
- In Q3 2025, Change in Accured Expenses rose 140.48% year-over-year to $85000.0; the TTM figure through Sep 2025 stood at $27000.0 (up 103.21% YoY), while the FY2024 annual figure was -$515000.0, up 67.49% from the prior year.
- Change in Accured Expenses for Q3 2025 stood at $85000.0, up from -$138000.0 in the prior quarter.
- The five-year high for Change in Accured Expenses was $462000.0 in Q2 2023, with the low at -$3.4 million in Q1 2021.
- The 5-year median for Change in Accured Expenses is -$186000.0 (2022), against an average of -$362526.3.
- Peak annual rise in Change in Accured Expenses reached 527.78% in 2023, while the deepest fall reached 636.36% in 2023.
- Cyclerion Therapeutics' Change in Accured Expenses stood at -$281000.0 in 2021, then surged by 33.81% to -$186000.0 in 2022, then sank by 97.31% to -$367000.0 in 2023, then soared by 88.83% to -$41000.0 in 2024, then jumped by 307.32% to $85000.0 in 2025.
- Business Quant data shows CYCN's Change in Accured Expenses at $85000.0 in Q3 2025, -$138000.0 in Q2 2025, and $121000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Cyclerion Therapeutics | 12.71 Mn | 9.47 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 85,000.00 |
| Sep 30, 2025 | 85,000.00 |
| Jun 30, 2025 | -138,000.00 |
| Jun 30, 2025 | -138,000.00 |
| Mar 31, 2025 | 121,000.00 |
| Mar 31, 2025 | 121,000.00 |
| Dec 31, 2024 | -41,000.00 |
| Dec 31, 2024 | -41,000.00 |
| Sep 30, 2024 | -210,000.00 |
| Sep 30, 2024 | -210,000.00 |
| Jun 30, 2024 | -76,000.00 |
| Jun 30, 2024 | -76,000.00 |
| Mar 31, 2024 | -188,000.00 |
| Mar 31, 2024 | -188,000.00 |
| Dec 31, 2023 | -367,000.00 |
| Dec 31, 2023 | -367,000.00 |
| Sep 30, 2023 | -1.30 Mn |
| Sep 30, 2023 | -1.30 Mn |
| Jun 30, 2023 | 462,000.00 |
| Jun 30, 2023 | 462,000.00 |